memo-inOncology – SPECIAL ISSUE

Find out the latest news from international oncology congresses and stay at the forefront of clinical innovation and advances in lung cancer research. Each SPECIAL ISSUE – CONGRESS REPORT features informative summaries of key topics from lung cancer to come out of a major international oncology congress.

The memo inOncology Medical education series: keeping oncologists at the forefront of lung cancer research. memo – inOncology Special Issue Preceptorship reports summarise the latest in lung cancer research and treatments to come out of our sponsored Preceptorship meeting series. The Fundamentals of Designing Clinical Trials series arms oncologists with the information they need to plan and conduct an oncology trial.

Congress reports

REGISTER

Get a notification for every published memo – inOncology SPECIAL ISSUE. Register below.


    LATEST NEWS

    EHA 2021 Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual ASCO/EHA/ICML 2021

    Report from the ASCO virtual Congress, 4th–8th June 2021, the Virtual Edition of the 26th European Hematology Associaton (EHA) Annual Congress, 9th–17th June 2021, and the Virtual Edition of the International Conference on Malignant Lymphoma, 18th-22nd June 2021

    Now available!

    ASCO 2021 English Cover

    memo – inOncology SPECIAL ISSUE

    Congress Report virtual ASCO 2021

    Report from the ASCO Virtual Congress, 4th–8th June 2021

    Now available!

    VIEW ALL OUR REPORTS

    EXPERT VIDEOS

    All videointerviews from virtual ASCO/EHA/ICML 2021

    Alvaro Alencar discusses which first-line treatment options might soon be established for newly diagnosed patients with mantle cell lymphoma who are not eligible for intensive therapy, what can be expected in terms of innovative approaches in the setting of R/R mantle cell lymphoma or marginal zone lymphoma and highlights the need for robust prognostic tools allowing stratification of treatment modalities.

    Matthew Davids depicts the most interesting trial results in the field of CLL treatment at the EHA 2021 congress, gives an outlook on the most promising agents currently tested for use not only in elderly but also in young, fit CLL patients and talks about combinations that might be implemented as pillars of CLL treatment based on current trials.

    Wojciech Jurczak gives an overview of the advantages of new BTK inhibitors, the results of the ALPINE trial comparing zanubrutinib with ibrutinib in patients with relapsed/refractory CLL/SLL and talks about which new developments can be expected in the field of innovative BTK inhibitors in the treatment of CLL and other indications.

    Carol Moreno highlights the CLL study results from EHA and ICML, enlarges on fixed-duration regimens in CLL treatment, the importance of long-term follow-up findings obtained in important trials such as CLL14 and ELEVATE-TN as well as data from the ALPINE and ELEVATE-RR studies and shares her thoughts on the role of new agents such as zanubrutinib in the overall treatment landscape.

    Anthony Mato talks about the study highlights presented at EHA and ICML, innovative treatment approaches currently tested for use in CLL that appear most promising and explains how the prognosis of CLL patients might change due to new therapies in the years to come and summarizes potential strategies to prevent and overcome resistance to targeted therapies.

    Christian Buske relates to recent developments with respect to the role of BTK inhibitors and their potential future combination partners in the treatment of patients with Waldenström’s macroglobulinemia, the results of the iNNOVATE study and personalized treatment according to genotypes.

    All videointerviews from virtual ASCO 2021

    Martin Reck compares the combination of novel immune checkpoint inhibitors with other drug classes to monotherapy in terms of efficacy and tolerability, discusses the role of biomarkers and the tumor microenvironment in terms of treatment decision and focuses on the potential predictive value of immune-related adverse events.

     

    David T. Cooke talks about health equity and health disparities relating to lung cancer management in the western world. He explains which factors based on ethnicity are likely to affect outcomes of lung cancer patients and how health disparities might be tackled in the long run at the public health level.

     

    Donald R. Harvey discusses lung cancer from the point of view of clinical pharmacology, targets in the area of antibody-drug conjugates, the role of proteolysis targeting chimeras (PROTACs) in the treatment landscape, highlights mechanisms of resistance to small molecule inhibitors and draws attention to clinical trial design to better meet the demands of modern drug development.

    Ferdinandos Skoulidis summarizes why the development of KRASG12C targeted therapies failed in the past, relates to new developments in the field of KRASG12C inhibition especially sotorasib and discusses the impact of co-mutations on personalized anticancer therapy.

    Luis G. Paz-Ares explains which notable developments are taking place in the field of small-cell lung cancer with respect to new targets and targeted agents, how chemotherapeutic standards will change in the management of patients with small-cell lung cancer and highlights the most relevant findings presented at ASCO 2021 in terms of targeted therapies.

    VIEW MEDICAL EDUCATION

    A CONGRESS RESOURCE

    For Oncologists and Hematologists